Loading...
Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia
There are five tyrosine kinase inhibitors (TKIs) that are currently approved (in the European Union and the United States) for the treatment of chronic myeloid leukaemia (CML) in the chronic phase (CP) and each of them has its own efficacy and toxicity profile. Oral ponatinib (Iclusig(®)) is a third...
Na minha lista:
| Udgivet i: | Ther Adv Hematol |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
SAGE Publications
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6399752/ https://ncbi.nlm.nih.gov/pubmed/30854182 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620719826444 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|